Your session is about to expire
← Back to Search
IMPT-314 for Non-Hodgkin's Lymphoma
Study Summary
This trial will test the safety of a new treatment to fight aggressive B-cell Non-Hodgkin Lymphoma (NHL). Up to 50 people will receive a single infusion of new CAR-transduced autologous T cells. Follow-up for 15 years.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have received certain treatments within specific time frames before joining.I am facing an urgent cancer-related health issue.My lymphoma is aggressive and confirmed by a biopsy.My heart has been affected by lymphoma.My condition has returned or didn't respond to treatment.I am fully active or restricted in physically strenuous activity but can do light work.I am experiencing side effects from previous cancer treatments.I have had a stem cell transplant from a donor.I had a stem cell transplant using my own cells within the last 6 weeks.I have an autoimmune disease that has caused organ damage or needed strong medication in the last 2 years.I have been cancer-free for over 3 years, except for non-melanoma skin cancer or carcinoma in situ.My cancer has spread to my brain or spinal cord.I am 18 years old or older.I have undergone at least 2 treatments including specific drugs.I have had gene-modified T cell therapy, but not for CD19.
- Group 1: Phase I Dose Level I Refractory disease or relapse within one year of first line therapy
- Group 2: Phase II Refractory disease or relapse within one year of first line therapy
- Group 3: Phase I Dose Level I CAR T experienced cohort
- Group 4: Phase I Dose Level I CAR T naïve cohort
- Group 5: Phase II CAR T experienced cohort
- Group 6: Phase II CAR T naïve cohort
- Group 7: Phase I Dose Level II Refractory disease or relapse within one year of first line therapy
- Group 8: Phase I Dose Level II CAR T naïve cohort
- Group 9: Phase I Dose Level II CAR T experienced cohort
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there numerous facilities conducting this clinical experiment in the city?
"The University of Iowa in Iowa City, Ohio, the UC Physicians Company LLC in Cincinnati, and the Huntsman Cancer Institute Salt Lake City are among the sites that will be participating in this experiment. Additionally, there are 4 other research centres collaborating on it."
Is this trial currently recruiting participants?
"According to clinicaltrials.gov, this experiment is not presently recruiting participants; although the listing was initially posted on April 12th 2023 and last updated around the same time. Despite this study's inactivity in patient recruitment at present, there are 1,750 other studies actively searching for volunteers right now."
Share this study with friends
Copy Link
Messenger